Second US patent granted
Montreal / April 05, 2024 – NexPlasmaGen is pleased to announce that on February 6, 2024, the 2nd U.S. patent (US ...
05 April, 2024 No commentMontreal / April 05, 2024 – NexPlasmaGen is pleased to announce that on February 6, 2024, the 2nd U.S. patent (US ...
05 April, 2024 No commentNEXPLASMAGEN TO PRESENT AT SEED SHOWCASE 2022 NexPlasmaGen will pitch its business opportunity to investors! Montreal/De...
24 December, 2021 No commentNexPlasmaGen is proud to announce that the preclinical trials program led by Dr. Philip Wong at the Centre Hospitaller d...
03 November, 2021 No commentMontreal / October 06, 2023 – NexPlasmaGen received a financial support of $219,500 from Quebec’s Ministère ...
06 October, 2023 1 CommentNexPlasmaGen Inc. is pleased to announce the completion of $795,000 in private and public investment from individuals, Aligo Innovation, the Quebec MEDTEQ program and the federal MITACS and CNRC-IRAP programs to accelerate the development of its patented cold ...
01 July, 2018 No commentNexPlasmaGen Inc. is pleased to announce that its patented cold plasma technology is in preparation for clinical investigation for the treatment of breast cancer. NexPlasmaGen has recently received financial support from private investors, NRC-IRAP and the Que...
02 January, 2021 No commentNexPlasmaGen is proud to announce that the preclinical trials program led by Dr. Philip Wong at the Centre Hospitaller de l’Université de Montréal was successfully completed. The first stage of the program demonstrated that NexPlasmaGen’s Convertible Pla...
03 November, 2021 No comment